Aβ 1-42-rage interaction disrupts tight junctions of the blood-brain barrier via Ca 2+-calcineurin signaling

Journal of Neuroscience

Volumn 32, Issue 26, 2012, Pages 8845-8854

  Kook, Sun Young ^a   Hong, Hyun Seok ^a,b   Moon, Minho ^a   Ha, Chang Man ^a   Chang, Sunghoe ^a   Mook Jung, Inhee ^a  

^a Seoul National University   (South Korea)

^b Medifron DBT   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN [1-42]; CALCINEURIN; CALCIUM ION; CLAUDIN 5; GELATINASE A; GELATINASE B; GLUCOSE TRANSPORTER; ILOMASTAT; OCCLUDIN; PROTEIN ZO1; TACROLIMUS; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; CALCIUM; CLAUDIN; DEXTRAN; DIPEPTIDE; DRUG DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUCOSE TRANSPORTER 1; IMMUNOGLOBULIN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PHOSPHOPROTEIN; PRESENILIN 1; PROTEINASE INHIBITOR; PSEN1 PROTEIN, HUMAN; SLC2A1 PROTEIN, MOUSE; ZONULA OCCLUDENS-1 PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TIGHT JUNCTION; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ZYMOGRAPHY; AGE; ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MICROVASCULATURE; MUTATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THREE DIMENSIONAL IMAGING; TRANSPORT AT THE CELLULAR LEVEL; ULTRASTRUCTURE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CALCINEURIN; CALCIUM; CELL LINE, TRANSFORMED; CLAUDINS; DEXTRANS; DIPEPTIDES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMAGING, THREE-DIMENSIONAL; IMMUNOSUPPRESSIVE AGENTS; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MICROVESSELS; MUTATION; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PRESENILIN-1; PROTEASE INHIBITORS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TACROLIMUS; TIGHT JUNCTIONS; TRANSFECTION;

EID: 84862885703     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.6102-11.2012     Document Type: Article

References (44)

1. Agostinho P, Lopes JP, Velez Z, Oliveira CR (2008) Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem Int 52:1226-1233.
2. Banks WA, Kastin AJ, Maness LM, Banks MF, Shayo M, McLay RN (1997) Interactions of beta-amyloids with the blood-brain barrier. AnnN Y Acad Sci 826:190-199.
3. Bond M, Fabunmi RP, Baker AH, Newby AC (1998) Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 435:29-34.
4. Brown RC, Morris AP, O'Neil RG (2007) Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130:17-30.
5. Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, Mook-Jung I (2009) RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 23:2639-2649.
6. Claudio L (1996) Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 91:6-14.
7. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277:32046-32053.
8. Deane R, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907-913.
9. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282: 11590-11601.
10. Doller A, Akool el-S, Müller R, Gutwein P, Kurowski C, Pfeilschifter J, Eberhardt W (2007) Molecular mechanisms of cyclosporin A inhibition of the cytokine-induced matrix metalloproteinase-9 in glomerular mesangial cells. J Am Soc Nephrol 18:581-592.
11. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46:1592-1596.
12. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM (1998) The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 273:29745-29753.
13. Garcia-Alloza M, Prada C, Lattarulo C, Fine S, Borrelli LA, Betensky R, Greenberg SM, Frosch MP, Bacskai BJ (2009) Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J Neurochem 109:1636-1647.
14. Gonzalez-Velasquez FJ, Kotarek JA, Moss MA (2008) Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J Neurochem 107:466-477.
15. Goodenough DA, Revel JP (1970) A fine structural analysis of intercellular junctions in the mouse liver. J Cell Biol 45:272-290.
16. Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57:173-185.
17. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, Peterson BL, Pieper CF (1998) Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's Disease. Neurology 51:159-162.
18. Hong HS, Hwang JY, Son SM, Kim YH, Moon M, Inhee MJ (2010) FK506 reduces amyloid plaque burden and induces MMP-9 in AbetaPP/PS1 double transgenic mice. J Alzheimers Dis 22:97-105.
19. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC (2002) The channel hypothesis of Alzheimer's disease: current status. Peptides 23:1311-1315.
20. Kalaria RN (1999) The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 893:113-125.
21. Kawahara M, Kuroda Y, Arispe N, Rojas E (2000) Alzheimer's betaamyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 275:14077-14083.
22. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381.
23. Lee JM, Yin KJ, Hsin I, Chen S, Fryer JD, Holtzman DM, Hsu CY, Xu J (2003) Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 54:379-382.
24. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH (2009) Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol 182:5778-5788.
25. Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX (2005) Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem 280:37755-37762.
26. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV (1998) Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 102:734-743.
27. Marco S, Skaper SD (2006) Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 401:219-224.
28. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45:537-541.
29. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12:376-389.
30. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129-10140.
31. Restituito S, Khatri L, Ninan I, Mathews PM, Liu X, Weinberg RJ, Ziff EB (2011) Synaptic autoregulation by metalloproteases and gammasecretase. J Neurosci 31:12083-12093.
32. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
33. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptorrelated protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499.
34. Simm A, Casselmann C, Schubert A, Hofmann S, Reimann A, Silber RE (2004) Age associated changes of AGE-receptor expression: RAGE upregulation is associated with human heart dysfunction. Exp Gerontol 39:407-413.
35. Snyder SH, Lai MM, Burnett PE (1998) Immunophilins in the nervous system. Neuron 21:283-294.
36. Strazielle N, Ghersi-Egea JF, Ghiso J, Dehouck MP, Frangione B, Patlak C, Fenstermacher J, Gorevic P (2000) In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability. J Neuropathol Exp Neurol 59:29-38.
37. Stuart RO, Sun A, Bush KT, Nigam SK (1996) Dependence of epithelial intercellular junction biogenesis on thapsigargin-sensitive intracellular calcium stores. J Biol Chem 271:13636-13641.
38. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA (2010) Amyloidbeta- induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated byMAPKactivation. J Cell Mol Med 14:1101-1112.
39. Warboys CM, Toh HB, Fraser PA (2009) Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci 50:1319-1328.
40. Wardlaw JM, Sandercock PA, Dennis MS, Starr J (2003) Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 34:806-812.
41. Watson PM, Anderson JM, Vanltallie CM, Doctrow SR (1991) The tightjunction- specific protein ZO-1 is a component of the human and rat blood-brain barriers. Neurosci Lett 129:6-10.
42. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691.
43. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27:697-709.
44. Zlokovic BV (2008) New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 5:409-414.